Zyus Life Sciences【ZYUS】銘柄情報

Zyus Life Sciences Corporation (ZYUS) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

0.495

( - )

買値

0.06

売値

0.50

出来高

平均取引量 (3 か月)

$ 10,019

財務取引量

0.00 日の範囲 0.00

0.395 52 週間の範囲 0.77

時価総額

39.859M

企業価値

54.649M

前日終値

0.495

始値

時刻

最終取引時間

VWAP

歳入

465k

純利益

-33.74M

発行済株式数

80,522,813

浮動株比率 (%)

50.72%

機関投資家保有比率 (%)

0.17%

配当利回り

PER

-1.1

株価売上高倍率 (PSR)

85.72

1 株当たり利益 (EPS)

-0.45

ベータ

0.45

ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates in Canada, the United States, Australia, and the European Union. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2... ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates in Canada, the United States, Australia, and the European Union. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2 clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries, arthritis, and cancer. ZYUS Life Sciences Corporation was founded in 2018 and is headquartered in Saskatoon, Canada. 詳細を表示

セクター

Health Care

業界

ウェブサイト

www.zyus.com

本社

Saskatoon, Canada

設立

2026

Zyus Life Sciences Corporation is listed in the Health Care sector of the トロントベンチャー取引所 with ticker ZYUS. The last closing price for Zyus Life Sciences was $0.50. Over the last year, Zyus Life Sciences shares have traded in a share price range of $ 0.395 to $ 0.77.

Zyus Life Sciences currently has 80,522,813 shares in issue. The market capitalisation of Zyus Life Sciences is $39.86 million. Zyus Life Sciences has a price to earnings ratio (PE ratio) of -1.10.

ZYUS Life Sciences Corporation Announces Closing of Fifth Tranche of Secured Loan Financing

ZYUS Life Sciences Corporation Announces Closing of Fifth Tranche of Secured Loan Financing Canada NewsWire...

ZYUS Life Sciences Corporation Announces Closing of Fourth Tranche of Secured Loan Financing

ZYUS Life Sciences Corporation Announces Closing of Fourth Tranche of Secured Loan Financing Canada...

ZYUS Life Sciences Corporation Announces Closing of Third Tranche of Secured Loan Financing

ZYUS Life Sciences Corporation Announces Closing of Third Tranche of Secured Loan Financing Canada NewsWire...

ZYUS Life Sciences Corporation Announces Closing of First Tranche of Secured Loan Financing and Provides an Update on its Annual Filings

ZYUS Life Sciences Corporation Announces Closing of First Tranche of Secured Loan Financing and Provides an...

ZYUS Announces Cease Trade Order

ZYUS Announces Cease Trade Order Canada NewsWire SASKATOON, SK, May 6, 2026 /NOT FOR DISTRIBUTION TO...

ZYUS Announces Delay in Its Annual Filings

ZYUS Announces Delay in Its Annual Filings Canada NewsWire SASKATOON, SK, April 30, 2026 /NOT FOR...

ZYUS Life Sciences Announces Completion of the Final Study Visit by the Last Patient in Phase 2a UTOPIA-1 Trial Evaluating Novel Non-Opioid Pain Drug

ZYUS Life Sciences Announces Completion of the Final Study Visit by the Last Patient in Phase 2a UTOPIA-1...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0.495	0.495	0.495	0	0	CS
4	0	0	0.495	0.495	0.495	0	0	CS
12	-0.005	-1	0.5	0.63	0.395	1482	0.4967556	CS
26	-0.205	-29.2857142857	0.7	0.7	0.395	4161	0.57596931	CS
52	-0.185	-27.2058823529	0.68	0.77	0.395	5165	0.64068871	CS
156	-0.495	-50	0.99	1.19	0.395	6857	0.82866726	CS
260	-2.005	-80.2	2.5	2.5	0.395	7965	0.92394947	CS